APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Opioid Induced Constipation (OIC) Drug

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Opioid Induced Constipation (OIC) Drug Industry Growth and Trends Forecast to 2032

Report ID 174019310120 December 2025117 pages

Choose your research edition.

Industry ResearchOpioid Induced Constipation (OIC) Drug Industry Research Report 2026130 pages · $2,950 USDIndustry Growth & TrendsGlobal Opioid Induced Constipation (OIC) Drug Industry Growth and Trends Forecast to 2032117 pages · $3,450 USDMarket StructureGlobal Opioid Induced Constipation (OIC) Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Opioid Induced Constipation (OIC) Drug Market Outlook and Growth Opportunities 2026209 pages · $4,250 USDMarket Analysis & ForecastGlobal Opioid Induced Constipation (OIC) Drug Market Analysis and Forecast 2026-2032202 pages · $4,950 USD

Market perspective

The global Opioid Induced Constipation (OIC) Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Opioid Induced Constipation (OIC) Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Opioid Induced Constipation (OIC) Drug is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Opioid Induced Constipation (OIC) Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Opioid Induced Constipation (OIC) Drug include Allergan, Bausch Health, C.B. Fleet Company, Cosmo Pharmaceuticals SA, Daewoong Pharmaceutical, Daiichi Sankyo Co, Ironwood Pharmaceuticals, Mundipharma International Limited and Nektar Therapeutics, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Opioid Induced Constipation (OIC) Drug market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Opioid Induced Constipation (OIC) Drug market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Opioid Induced Constipation (OIC) Drug market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Opioid Induced Constipation (OIC) Drug.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Opioid Induced Constipation (OIC) Drug market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Opioid Induced Constipation (OIC) Drug Market by Company

Allergan

Bausch Health

C.B. Fleet Company

Cosmo Pharmaceuticals SA

Daewoong Pharmaceutical

Daiichi Sankyo Co

Ironwood Pharmaceuticals

Mundipharma International Limited

Nektar Therapeutics

Ono Pharmaceutical

Progenics Pharmaceuticals

Purdue Pharma

S.L.A. Pharma

Shionogi &

Sucampo Pharmaceuticals

Theravance Biopharma

Pfizer

Takeda Pharmaceutical Company Limited

Opioid Induced Constipation (OIC) Drug Segment by Type

Naldemedine

Lubiprostone

Methyl Naltrexone Bromide

Alvimopan

Other

Opioid Induced Constipation (OIC) Drug Segment by Application

Retail Pharmacies

Online Pharmacies

Hospital Pharmacies

Opioid Induced Constipation (OIC) Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Opioid Induced Constipation (OIC) Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Opioid Induced Constipation (OIC) Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Opioid Induced Constipation (OIC) Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Opioid Induced Constipation (OIC) Drug manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Opioid Induced Constipation (OIC) Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Naldemedine Table 2. Major Company of Lubiprostone Table 3. Major Company of Methyl Naltrexone Bromide Table 4. Major Company of Alvimopan Table 5. Major Company of Other Table 6. Global Opioid Induced Constipation (OIC) Drug Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 7. Global Opioid Induced Constipation (OIC) Drug Sales by Type (2021-2026) & (K Units) Table 8. Global Opioid Induced Constipation (OIC) Drug Sales Market Share in Volume by Type (2021-2026) Table 9. Global Opioid Induced Constipation (OIC) Drug Sales by Type (2021-2026) & (US$ Million) Table 10. Global Opioid Induced Constipation (OIC) Drug Sales Market Share in Value by Type (2021-2026) Table 11. Global Opioid Induced Constipation (OIC) Drug Price by Type (2021-2026) & (US$/Unit) Table 12. Global Opioid Induced Constipation (OIC) Drug Sales by Type (2027-2032) & (K Units) Table 13. Global Opioid Induced Constipation (OIC) Drug Sales Market Share in Volume by Type (2027-2032) Table 14. Global Opioid Induced Constipation (OIC) Drug Sales by Type (2027-2032) & (US$ Million) Table 15. Global Opioid Induced Constipation (OIC) Drug Sales Market Share in Value by Type (2027-2032) Table 16. Global Opioid Induced Constipation (OIC) Drug Price by Type (2027-2032) & (US$/Unit) Table 17. North America Opioid Induced Constipation (OIC) Drug Sales by Type (2021-2026) & (K Units) Table 18. North America Opioid Induced Constipation (OIC) Drug Sales by Type (2021-2026) & (US$ Million) Table 19. Europe Opioid Induced Constipation (OIC) Drug Sales by Type (2021-2026) & (K Units) Table 20. Europe Opioid Induced Constipation (OIC) Drug Sales by Type (2021-2026) & (US$ Million) Table 21. Asia-Pacific Opioid Induced Constipation (OIC) Drug Sales by Type (2021-2026) & (K Units) Table 22. Asia-Pacific Opioid Induced Constipation (OIC) Drug Sales by Type (2021-2026) & (US$ Million) Table 23. Latin America Opioid Induced Constipation (OIC) Drug Sales by Type (2021-2026) & (K Units) Table 24. Latin America Opioid Induced Constipation (OIC) Drug Sales by Type (2021-2026) & (US$ Million) Table 25. Middle East and Africa Opioid Induced Constipation (OIC) Drug Sales by Type (2021-2026) & (K Units) Table 26. Middle East and Africa Opioid Induced Constipation (OIC) Drug Sales by Type (2021-2026) & (US$ Million) Table 27. Opioid Induced Constipation (OIC) Drug Industry Trends Table 28. Opioid Induced Constipation (OIC) Drug Industry Drivers Table 29. Opioid Induced Constipation (OIC) Drug Industry Opportunities and Challenges Table 30. Opioid Induced Constipation (OIC) Drug Industry Restraints Table 31. Global Opioid Induced Constipation (OIC) Drug Sales Revenue by Company (US$ Million) & (2021-2026) Table 32. Global Opioid Induced Constipation (OIC) Drug Revenue Market Share by Company (2021-2026) Table 33. Global Opioid Induced Constipation (OIC) Drug Sales by Company (2021-2026) & (K Units) Table 34. Global Opioid Induced Constipation (OIC) Drug Sales Share by Company (2021-2026) Table 35. Global Opioid Induced Constipation (OIC) Drug Market Price by Company (2021-2026) & (US$/Unit) Table 36. Global Opioid Induced Constipation (OIC) Drug Industry Company Ranking, 2024 VS 2025 VS 2026 Table 37. Global Opioid Induced Constipation (OIC) Drug Major Company Production Sites and Headquarters Table 38. Global Opioid Induced Constipation (OIC) Drug Company, Product Type & Application Table 39. Global Opioid Induced Constipation (OIC) Drug Company Establishment Date Table 40. Global Company Market Concentration Ratio (CR5 and HHI) Table 41. Global Opioid Induced Constipation (OIC) Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 42. Global Opioid Induced Constipation (OIC) Drug Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 43. Global Opioid Induced Constipation (OIC) Drug Sales by Region (2021-2026) & (K Units) Table 44. Global Opioid Induced Constipation (OIC) Drug Sales Market Share in Volume by Region (2021-2026) Table 45. Global Opioid Induced Constipation (OIC) Drug Sales by Region (2021-2026) & (US$ Million) Table 46. Global Opioid Induced Constipation (OIC) Drug Sales Market Share in Value by Region (2021-2026) Table 47. Global Opioid Induced Constipation (OIC) Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 48. Global Opioid Induced Constipation (OIC) Drug Sales by Region (2027-2032) & (K Units) Table 49. Global Opioid Induced Constipation (OIC) Drug Sales Market Share in Volume by Region (2027-2032) Table 50. Global Opioid Induced Constipation (OIC) Drug Sales by Region (2027-2032) & (US$ Million) Table 51. Global Opioid Induced Constipation (OIC) Drug Sales Market Share in Value by Region (2027-2032) Table 52. Global Opioid Induced Constipation (OIC) Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 53. Global Opioid Induced Constipation (OIC) Drug Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 54. Global Opioid Induced Constipation (OIC) Drug Sales by Application (2021-2026) & (K Units) Table 55. Global Opioid Induced Constipation (OIC) Drug Sales Market Share in Volume by Application (2021-2026) Table 56. Global Opioid Induced Constipation (OIC) Drug Sales by Application (2021-2026) & (US$ Million) Table 57. Global Opioid Induced Constipation (OIC) Drug Sales Market Share in Value by Application (2021-2026) Table 58. Global Opioid Induced Constipation (OIC) Drug Price by Application (2021-2026) & (US$/Unit) Table 59. Global Opioid Induced Constipation (OIC) Drug Sales by Application (2027-2032) & (K Units) Table 60. Global Opioid Induced Constipation (OIC) Drug Sales Market Share in Volume by Application (2027-2032) Table 61. Global Opioid Induced Constipation (OIC) Drug Sales by Application (2027-2032) & (US$ Million) Table 62. Global Opioid Induced Constipation (OIC) Drug Sales Market Share in Value by Application (2027-2032) Table 63. Global Opioid Induced Constipation (OIC) Drug Price by Application (2027-2032) & (US$/Unit) Table 64. North America Opioid Induced Constipation (OIC) Drug Sales by Application (2021-2026) & (K Units) Table 65. North America Opioid Induced Constipation (OIC) Drug Sales by Application (2021-2026) & (US$ Million) Table 66. Europe Opioid Induced Constipation (OIC) Drug Sales by Application (2021-2026) & (K Units) Table 67. Europe Opioid Induced Constipation (OIC) Drug Sales by Application (2021-2026) & (US$ Million) Table 68. Asia-Pacific Opioid Induced Constipation (OIC) Drug Sales by Application (2021-2026) & (K Units) Table 69. Asia-Pacific Opioid Induced Constipation (OIC) Drug Sales by Application (2021-2026) & (US$ Million) Table 70. Latin America Opioid Induced Constipation (OIC) Drug Sales by Application (2021-2026) & (K Units) Table 71. Latin America Opioid Induced Constipation (OIC) Drug Sales by Application (2021-2026) & (US$ Million) Table 72. Middle East and Africa Opioid Induced Constipation (OIC) Drug Sales by Application (2021-2026) & (K Units) Table 73. Middle East and Africa Opioid Induced Constipation (OIC) Drug Sales by Application (2021-2026) & (US$ Million) Table 74. Allergan Company Information Table 75. Allergan Business Overview Table 76. Allergan Opioid Induced Constipation (OIC) Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Allergan Opioid Induced Constipation (OIC) Drug Product Portfolio Table 78. Allergan Recent Development Table 79. Bausch Health Company Information Table 80. Bausch Health Business Overview Table 81. Bausch Health Opioid Induced Constipation (OIC) Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. Bausch Health Opioid Induced Constipation (OIC) Drug Product Portfolio Table 83. Bausch Health Recent Development Table 84. C.B. Fleet Company Company Information Table 85. C.B. Fleet Company Business Overview Table 86. C.B. Fleet Company Opioid Induced Constipation (OIC) Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. C.B. Fleet Company Opioid Induced Constipation (OIC) Drug Product Portfolio Table 88. C.B. Fleet Company Recent Development Table 89. Cosmo Pharmaceuticals SA Company Information Table 90. Cosmo Pharmaceuticals SA Business Overview Table 91. Cosmo Pharmaceuticals SA Opioid Induced Constipation (OIC) Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Cosmo Pharmaceuticals SA Opioid Induced Constipation (OIC) Drug Product Portfolio Table 93. Cosmo Pharmaceuticals SA Recent Development Table 94. Daewoong Pharmaceutical Company Information Table 95. Daewoong Pharmaceutical Business Overview Table 96. Daewoong Pharmaceutical Opioid Induced Constipation (OIC) Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Daewoong Pharmaceutical Opioid Induced Constipation (OIC) Drug Product Portfolio Table 98. Daewoong Pharmaceutical Recent Development Table 99. Daiichi Sankyo Co Company Information Table 100. Daiichi Sankyo Co Business Overview Table 101. Daiichi Sankyo Co Opioid Induced Constipation (OIC) Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Daiichi Sankyo Co Opioid Induced Constipation (OIC) Drug Product Portfolio Table 103. Daiichi Sankyo Co Recent Development Table 104. Ironwood Pharmaceuticals Company Information Table 105. Ironwood Pharmaceuticals Business Overview Table 106. Ironwood Pharmaceuticals Opioid Induced Constipation (OIC) Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Ironwood Pharmaceuticals Opioid Induced Constipation (OIC) Drug Product Portfolio Table 108. Ironwood Pharmaceuticals Recent Development Table 109. Mundipharma International Limited Company Information Table 110. Mundipharma International Limited Business Overview Table 111. Mundipharma International Limited Opioid Induced Constipation (OIC) Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. Mundipharma International Limited Opioid Induced Constipation (OIC) Drug Product Portfolio Table 113. Mundipharma International Limited Recent Development Table 114. Nektar Therapeutics Company Information Table 115. Nektar Therapeutics Business Overview Table 116. Nektar Therapeutics Opioid Induced Constipation (OIC) Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. Nektar Therapeutics Opioid Induced Constipation (OIC) Drug Product Portfolio Table 118. Nektar Therapeutics Recent Development Table 119. Ono Pharmaceutical Company Information Table 120. Ono Pharmaceutical Business Overview Table 121. Ono Pharmaceutical Opioid Induced Constipation (OIC) Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 122. Ono Pharmaceutical Opioid Induced Constipation (OIC) Drug Product Portfolio Table 123. Ono Pharmaceutical Recent Development Table 124. Progenics Pharmaceuticals Company Information Table 125. Progenics Pharmaceuticals Business Overview Table 126. Progenics Pharmaceuticals Opioid Induced Constipation (OIC) Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 127. Progenics Pharmaceuticals Opioid Induced Constipation (OIC) Drug Product Portfolio Table 128. Progenics Pharmaceuticals Recent Development Table 129. Purdue Pharma Company Information Table 130. Purdue Pharma Business Overview Table 131. Purdue Pharma Opioid Induced Constipation (OIC) Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 132. Purdue Pharma Opioid Induced Constipation (OIC) Drug Product Portfolio Table 133. Purdue Pharma Recent Development Table 134. S.L.A. Pharma Company Information Table 135. S.L.A. Pharma Business Overview Table 136. S.L.A. Pharma Opioid Induced Constipation (OIC) Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 137. S.L.A. Pharma Opioid Induced Constipation (OIC) Drug Product Portfolio Table 138. S.L.A. Pharma Recent Development Table 139. Shionogi & Company Information Table 140. Shionogi & Business Overview Table 141. Shionogi & Opioid Induced Constipation (OIC) Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 142. Shionogi & Opioid Induced Constipation (OIC) Drug Product Portfolio Table 143. Shionogi & Recent Development Table 144. Sucampo Pharmaceuticals Company Information Table 145. Sucampo Pharmaceuticals Business Overview Table 146. Sucampo Pharmaceuticals Opioid Induced Constipation (OIC) Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 147. Sucampo Pharmaceuticals Opioid Induced Constipation (OIC) Drug Product Portfolio Table 148. Sucampo Pharmaceuticals Recent Development Table 149. Theravance Biopharma Company Information Table 150. Theravance Biopharma Business Overview Table 151. Theravance Biopharma Opioid Induced Constipation (OIC) Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 152. Theravance Biopharma Opioid Induced Constipation (OIC) Drug Product Portfolio Table 153. Theravance Biopharma Recent Development Table 154. Pfizer Company Information Table 155. Pfizer Business Overview Table 156. Pfizer Opioid Induced Constipation (OIC) Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 157. Pfizer Opioid Induced Constipation (OIC) Drug Product Portfolio Table 158. Pfizer Recent Development Table 159. Takeda Pharmaceutical Company Limited Company Information Table 160. Takeda Pharmaceutical Company Limited Business Overview Table 161. Takeda Pharmaceutical Company Limited Opioid Induced Constipation (OIC) Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 162. Takeda Pharmaceutical Company Limited Opioid Induced Constipation (OIC) Drug Product Portfolio Table 163. Takeda Pharmaceutical Company Limited Recent Development Table 164. North America Opioid Induced Constipation (OIC) Drug Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 165. North America Opioid Induced Constipation (OIC) Drug Sales by Country (2021-2026) & (K Units) Table 166. North America Opioid Induced Constipation (OIC) Drug Sales Market Share by Country (2021-2026) Table 167. North America Opioid Induced Constipation (OIC) Drug Sales Forecast by Country (2027-2032) & (K Units) Table 168. North America Opioid Induced Constipation (OIC) Drug Sales Market Share Forecast by Country (2027-2032) Table 169. North America Opioid Induced Constipation (OIC) Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 170. North America Opioid Induced Constipation (OIC) Drug Market Size by Country (2021-2026) & (US$ Million) Table 171. North America Opioid Induced Constipation (OIC) Drug Market Share by Country (2021-2026) Table 172. North America Opioid Induced Constipation (OIC) Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 173. North America Opioid Induced Constipation (OIC) Drug Market Share Forecast by Country (2027-2032) Table 174. Europe Opioid Induced Constipation (OIC) Drug Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 175. Europe Opioid Induced Constipation (OIC) Drug Sales by Country (2021-2026) & (K Units) Table 176. Europe Opioid Induced Constipation (OIC) Drug Sales Market Share by Country (2021-2026) Table 177. Europe Opioid Induced Constipation (OIC) Drug Sales Forecast by Country (2027-2032) & (K Units) Table 178. Europe Opioid Induced Constipation (OIC) Drug Sales Market Share Forecast by Country (2027-2032) Table 179. Europe Opioid Induced Constipation (OIC) Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 180. Europe Opioid Induced Constipation (OIC) Drug Market Size by Country (2021-2026) & (US$ Million) Table 181. Europe Opioid Induced Constipation (OIC) Drug Market Share by Country (2021-2026) Table 182. Europe Opioid Induced Constipation (OIC) Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 183. Europe Opioid Induced Constipation (OIC) Drug Market Share Forecast by Country (2027-2032) Table 184. Asia-Pacific Opioid Induced Constipation (OIC) Drug Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 185. Asia-Pacific Opioid Induced Constipation (OIC) Drug Sales by Country (2021-2026) & (K Units) Table 186. Asia-Pacific Opioid Induced Constipation (OIC) Drug Sales Market Share by Country (2021-2026) Table 187. Asia-Pacific Opioid Induced Constipation (OIC) Drug Sales Forecast by Country (2027-2032) & (K Units) Table 188. Asia-Pacific Opioid Induced Constipation (OIC) Drug Sales Market Share Forecast by Country (2027-2032) Table 189. Asia-Pacific Opioid Induced Constipation (OIC) Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 190. Asia-Pacific Opioid Induced Constipation (OIC) Drug Market Size by Country (2021-2026) & (US$ Million) Table 191. Asia-Pacific Opioid Induced Constipation (OIC) Drug Market Share by Country (2021-2026) Table 192. Asia-Pacific Opioid Induced Constipation (OIC) Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 193. Asia-Pacific Opioid Induced Constipation (OIC) Drug Market Share Forecast by Country (2027-2032) Table 194. Latin America Opioid Induced Constipation (OIC) Drug Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 195. Latin America Opioid Induced Constipation (OIC) Drug Sales by Country (2021-2026) & (K Units) Table 196. Latin America Opioid Induced Constipation (OIC) Drug Sales Market Share by Country (2021-2026) Table 197. Latin America Opioid Induced Constipation (OIC) Drug Sales Forecast by Country (2027-2032) & (K Units) Table 198. Latin America Opioid Induced Constipation (OIC) Drug Sales Market Share Forecast by Country (2027-2032) Table 199. Latin America Opioid Induced Constipation (OIC) Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 200. Latin America Opioid Induced Constipation (OIC) Drug Market Size by Country (2021-2026) & (US$ Million) Table 201. Latin America Opioid Induced Constipation (OIC) Drug Market Share by Country (2021-2026) Table 202. Latin America Opioid Induced Constipation (OIC) Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 203. Latin America Opioid Induced Constipation (OIC) Drug Market Share Forecast by Country (2027-2032) Table 204. Middle East and Africa Opioid Induced Constipation (OIC) Drug Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 205. Middle East and Africa Opioid Induced Constipation (OIC) Drug Sales by Country (2021-2026) & (K Units) Table 206. Middle East and Africa Opioid Induced Constipation (OIC) Drug Sales Market Share by Country (2021-2026) Table 207. Middle East and Africa Opioid Induced Constipation (OIC) Drug Sales Forecast by Country (2027-2032) & (K Units) Table 208. Middle East and Africa Opioid Induced Constipation (OIC) Drug Sales Market Share Forecast by Country (2027-2032) Table 209. Middle East and Africa Opioid Induced Constipation (OIC) Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 210. Middle East and Africa Opioid Induced Constipation (OIC) Drug Market Size by Country (2021-2026) & (US$ Million) Table 211. Middle East and Africa Opioid Induced Constipation (OIC) Drug Market Share by Country (2021-2026) Table 212. Middle East and Africa Opioid Induced Constipation (OIC) Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 213. Middle East and Africa Opioid Induced Constipation (OIC) Drug Market Share Forecast by Country (2027-2032) Table 214. Key Raw Materials Table 215. Raw Materials Key Suppliers Table 216. Opioid Induced Constipation (OIC) Drug Distributors List Table 217. Opioid Induced Constipation (OIC) Drug Customers List Table 218. Research Programs/Design for This Report Table 219. Authors List of This Report Table 220. Secondary Sources Table 221. Primary Sources List of Figures Figure 1. Opioid Induced Constipation (OIC) Drug Image Figure 2. Global Opioid Induced Constipation (OIC) Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Opioid Induced Constipation (OIC) Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Opioid Induced Constipation (OIC) Drug Sales (2021-2032) & (K Units) Figure 5. Naldemedine Image Figure 6. Global Naldemedine Sales YoY Growth (2021-2032) & (K Units) Figure 7. Lubiprostone Image Figure 8. Global Lubiprostone Sales YoY Growth (2021-2032) & (K Units) Figure 9. Methyl Naltrexone Bromide Image Figure 10. Global Methyl Naltrexone Bromide Sales YoY Growth (2021-2032) & (K Units) Figure 11. Alvimopan Image Figure 12. Global Alvimopan Sales YoY Growth (2021-2032) & (K Units) Figure 13. Other Image Figure 14. Global Other Sales YoY Growth (2021-2032) & (K Units) Figure 15. Global Opioid Induced Constipation (OIC) Drug Market Size Overview by Type (2021-2032) & (US$ Million) Figure 16. Global Opioid Induced Constipation (OIC) Drug Market Share by Type 2025 VS 2032 Figure 17. North America Opioid Induced Constipation (OIC) Drug Sales Market Share in Volume by Type in 2025 Figure 18. North America Opioid Induced Constipation (OIC) Drug Sales Market Share in Value by Type in 2025 Figure 19. Europe Opioid Induced Constipation (OIC) Drug Sales Market Share in Volume by Type in 2025 Figure 20. Europe Opioid Induced Constipation (OIC) Drug Sales Market Share in Value by Type in 2025 Figure 21. Asia-Pacific Opioid Induced Constipation (OIC) Drug Sales Market Share in Volume by Type in 2025 Figure 22. Asia-Pacific Opioid Induced Constipation (OIC) Drug Sales Market Share in Value by Type in 2025 Figure 23. Latin America Opioid Induced Constipation (OIC) Drug Sales Market Share in Volume by Type in 2025 Figure 24. Latin America Opioid Induced Constipation (OIC) Drug Sales Market Share in Value by Type in 2025 Figure 25. Middle East and Africa Opioid Induced Constipation (OIC) Drug Sales Market Share in Volume by Type in 2025 Figure 26. Middle East and Africa Opioid Induced Constipation (OIC) Drug Sales Market Share in Value by Type in 2025 Figure 27. Global Top 5 and 10 Opioid Induced Constipation (OIC) Drug Players Market Share by Revenue in 2025 Figure 28. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 29. Retail Pharmacies Image Figure 30. Global Retail Pharmacies Sales YoY Growth (2021-2032) & (K Units) Figure 31. Online Pharmacies Image Figure 32. Global Online Pharmacies Sales YoY Growth (2021-2032) & (K Units) Figure 33. Hospital Pharmacies Image Figure 34. Global Hospital Pharmacies Sales YoY Growth (2021-2032) & (K Units) Figure 35. Global Opioid Induced Constipation (OIC) Drug Market Size Overview by Application (2021-2032) & (US$ Million) Figure 36. Global Opioid Induced Constipation (OIC) Drug Market Share by Application 2025 VS 2032 Figure 37. North America Opioid Induced Constipation (OIC) Drug Sales Market Share in Volume by Application in 2025 Figure 38. North America Opioid Induced Constipation (OIC) Drug Sales Market Share in Value by Application in 2025 Figure 39. Europe Opioid Induced Constipation (OIC) Drug Sales Market Share in Volume by Application in 2025 Figure 40. Europe Opioid Induced Constipation (OIC) Drug Sales Market Share in Value by Application in 2025 Figure 41. Asia-Pacific Opioid Induced Constipation (OIC) Drug Sales Market Share in Volume by Application in 2025 Figure 42. Asia-Pacific Opioid Induced Constipation (OIC) Drug Sales Market Share in Value by Application in 2025 Figure 43. Latin America Opioid Induced Constipation (OIC) Drug Sales Market Share in Volume by Application in 2025 Figure 44. Latin America Opioid Induced Constipation (OIC) Drug Sales Market Share in Value by Application in 2025 Figure 45. Middle East and Africa Opioid Induced Constipation (OIC) Drug Sales Market Share in Volume by Application in 2025 Figure 46. Middle East and Africa Opioid Induced Constipation (OIC) Drug Sales Market Share in Value by Application in 2025 Figure 47. North America Opioid Induced Constipation (OIC) Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 48. North America Opioid Induced Constipation (OIC) Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 49. North America Opioid Induced Constipation (OIC) Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. North America Opioid Induced Constipation (OIC) Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Europe Opioid Induced Constipation (OIC) Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 52. Europe Opioid Induced Constipation (OIC) Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. Europe Opioid Induced Constipation (OIC) Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. Europe Opioid Induced Constipation (OIC) Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Asia-Pacific Opioid Induced Constipation (OIC) Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 56. Asia-Pacific Opioid Induced Constipation (OIC) Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Asia-Pacific Opioid Induced Constipation (OIC) Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Asia-Pacific Opioid Induced Constipation (OIC) Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Latin America Opioid Induced Constipation (OIC) Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 60. Latin America Opioid Induced Constipation (OIC) Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 61. Latin America Opioid Induced Constipation (OIC) Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Latin America Opioid Induced Constipation (OIC) Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 63. Middle East and Africa Opioid Induced Constipation (OIC) Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 64. Middle East and Africa Opioid Induced Constipation (OIC) Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 65. Middle East and Africa Opioid Induced Constipation (OIC) Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 66. Middle East and Africa Opioid Induced Constipation (OIC) Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 67. Opioid Induced Constipation (OIC) Drug Value Chain Figure 68. Key Raw Materials Price Figure 69. Manufacturing Cost Structure Figure 70. Opioid Induced Constipation (OIC) Drug Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Naldemedine
  • Lubiprostone
  • Methyl Naltrexone Bromide
  • Alvimopan
  • Other
Applications
  • Retail Pharmacies
  • Online Pharmacies
  • Hospital Pharmacies
Companies covered
  • Allergan
  • Bausch Health
  • C.B. Fleet Company
  • Cosmo Pharmaceuticals SA
  • Daewoong Pharmaceutical
  • Daiichi Sankyo Co
  • Ironwood Pharmaceuticals
  • Mundipharma International Limited
  • Nektar Therapeutics
  • Ono Pharmaceutical
  • Progenics Pharmaceuticals
  • Purdue Pharma
  • S.L.A. Pharma
  • Shionogi &
  • Sucampo Pharmaceuticals
  • Theravance Biopharma
  • Pfizer
  • Takeda Pharmaceutical Company Limited

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Opioid Induced Constipation (OIC) Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Opioid Induced Constipation (OIC) Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Opioid Induced Constipation (OIC) Drug Market by Type
  6. 1.3.1 Naldemedine
  7. 1.3.2 Lubiprostone
  8. 1.3.3 Methyl Naltrexone Bromide
  9. 1.3.4 Alvimopan
  10. 1.3.5 Other
  11. 1.4 Global Opioid Induced Constipation (OIC) Drug Market Size by Type
  12. 1.4.1 Global Opioid Induced Constipation (OIC) Drug Market Size Overview by Type (2021-2032)
  13. 1.4.2 Global Opioid Induced Constipation (OIC) Drug Historic Market Size Review by Type (2021-2026)
  14. 1.4.3 Global Opioid Induced Constipation (OIC) Drug Forecasted Market Size by Type (2027-2032)
  15. 1.5 Key Regions Market Size by Type
  16. 1.5.1 North America Opioid Induced Constipation (OIC) Drug Sales Breakdown by Type (2021-2026)
  17. 1.5.2 Europe Opioid Induced Constipation (OIC) Drug Sales Breakdown by Type (2021-2026)
  18. 1.5.3 Asia-Pacific Opioid Induced Constipation (OIC) Drug Sales Breakdown by Type (2021-2026)
  19. 1.5.4 South America Opioid Induced Constipation (OIC) Drug Sales Breakdown by Type (2021-2026)
  20. 1.5.5 Middle East and Africa Opioid Induced Constipation (OIC) Drug Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Opioid Induced Constipation (OIC) Drug Industry Trends
  2. 2.2 Opioid Induced Constipation (OIC) Drug Industry Drivers
  3. 2.3 Opioid Induced Constipation (OIC) Drug Industry Opportunities and Challenges
  4. 2.4 Opioid Induced Constipation (OIC) Drug Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Opioid Induced Constipation (OIC) Drug Revenue (2021-2026)
  2. 3.2 Global Top Players by Opioid Induced Constipation (OIC) Drug Sales (2021-2026)
  3. 3.3 Global Top Players by Opioid Induced Constipation (OIC) Drug Price (2021-2026)
  4. 3.4 Global Opioid Induced Constipation (OIC) Drug Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Opioid Induced Constipation (OIC) Drug Major Company Production Sites & Headquarters
  6. 3.6 Global Opioid Induced Constipation (OIC) Drug Company, Product Type & Application
  7. 3.7 Global Opioid Induced Constipation (OIC) Drug Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Opioid Induced Constipation (OIC) Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Opioid Induced Constipation (OIC) Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Opioid Induced Constipation (OIC) Drug Tier 1, Tier 2, and Tier 3
4 Opioid Induced Constipation (OIC) Drug Regional Status and Outlook
  1. 4.1 Global Opioid Induced Constipation (OIC) Drug Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Opioid Induced Constipation (OIC) Drug Historic Market Size by Region
  3. 4.2.1 Global Opioid Induced Constipation (OIC) Drug Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Opioid Induced Constipation (OIC) Drug Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Opioid Induced Constipation (OIC) Drug Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Opioid Induced Constipation (OIC) Drug Forecasted Market Size by Region
  7. 4.3.1 Global Opioid Induced Constipation (OIC) Drug Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Opioid Induced Constipation (OIC) Drug Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Opioid Induced Constipation (OIC) Drug Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Opioid Induced Constipation (OIC) Drug by Application
  1. 5.1 Opioid Induced Constipation (OIC) Drug Market by Application
  2. 5.1.1 Retail Pharmacies
  3. 5.1.2 Online Pharmacies
  4. 5.1.3 Hospital Pharmacies
  5. 5.2 Global Opioid Induced Constipation (OIC) Drug Market Size by Application
  6. 5.2.1 Global Opioid Induced Constipation (OIC) Drug Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Opioid Induced Constipation (OIC) Drug Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Opioid Induced Constipation (OIC) Drug Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Opioid Induced Constipation (OIC) Drug Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Opioid Induced Constipation (OIC) Drug Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Opioid Induced Constipation (OIC) Drug Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Opioid Induced Constipation (OIC) Drug Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Opioid Induced Constipation (OIC) Drug Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Allergan
  2. 6.1.1 Allergan Company Information
  3. 6.1.2 Allergan Business Overview
  4. 6.1.3 Allergan Opioid Induced Constipation (OIC) Drug Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Allergan Opioid Induced Constipation (OIC) Drug Product Portfolio
  6. 6.1.5 Allergan Recent Developments
  7. 6.2 Bausch Health
  8. 6.2.1 Bausch Health Company Information
  9. 6.2.2 Bausch Health Business Overview
  10. 6.2.3 Bausch Health Opioid Induced Constipation (OIC) Drug Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Bausch Health Opioid Induced Constipation (OIC) Drug Product Portfolio
  12. 6.2.5 Bausch Health Recent Developments
  13. 6.3 C.B. Fleet Company
  14. 6.3.1 C.B. Fleet Company Company Information
  15. 6.3.2 C.B. Fleet Company Business Overview
  16. 6.3.3 C.B. Fleet Company Opioid Induced Constipation (OIC) Drug Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 C.B. Fleet Company Opioid Induced Constipation (OIC) Drug Product Portfolio
  18. 6.3.5 C.B. Fleet Company Recent Developments
  19. 6.4 Cosmo Pharmaceuticals SA
  20. 6.4.1 Cosmo Pharmaceuticals SA Company Information
  21. 6.4.2 Cosmo Pharmaceuticals SA Business Overview
  22. 6.4.3 Cosmo Pharmaceuticals SA Opioid Induced Constipation (OIC) Drug Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Cosmo Pharmaceuticals SA Opioid Induced Constipation (OIC) Drug Product Portfolio
  24. 6.4.5 Cosmo Pharmaceuticals SA Recent Developments
  25. 6.5 Daewoong Pharmaceutical
  26. 6.5.1 Daewoong Pharmaceutical Company Information
  27. 6.5.2 Daewoong Pharmaceutical Business Overview
  28. 6.5.3 Daewoong Pharmaceutical Opioid Induced Constipation (OIC) Drug Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Daewoong Pharmaceutical Opioid Induced Constipation (OIC) Drug Product Portfolio
  30. 6.5.5 Daewoong Pharmaceutical Recent Developments
  31. 6.6 Daiichi Sankyo Co
  32. 6.6.1 Daiichi Sankyo Co Company Information
  33. 6.6.2 Daiichi Sankyo Co Business Overview
  34. 6.6.3 Daiichi Sankyo Co Opioid Induced Constipation (OIC) Drug Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Daiichi Sankyo Co Opioid Induced Constipation (OIC) Drug Product Portfolio
  36. 6.6.5 Daiichi Sankyo Co Recent Developments
  37. 6.7 Ironwood Pharmaceuticals
  38. 6.7.1 Ironwood Pharmaceuticals Company Information
  39. 6.7.2 Ironwood Pharmaceuticals Business Overview
  40. 6.7.3 Ironwood Pharmaceuticals Opioid Induced Constipation (OIC) Drug Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Ironwood Pharmaceuticals Opioid Induced Constipation (OIC) Drug Product Portfolio
  42. 6.7.5 Ironwood Pharmaceuticals Recent Developments
  43. 6.8 Mundipharma International Limited
  44. 6.8.1 Mundipharma International Limited Company Information
  45. 6.8.2 Mundipharma International Limited Business Overview
  46. 6.8.3 Mundipharma International Limited Opioid Induced Constipation (OIC) Drug Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Mundipharma International Limited Opioid Induced Constipation (OIC) Drug Product Portfolio
  48. 6.8.5 Mundipharma International Limited Recent Developments
  49. 6.9 Nektar Therapeutics
  50. 6.9.1 Nektar Therapeutics Company Information
  51. 6.9.2 Nektar Therapeutics Business Overview
  52. 6.9.3 Nektar Therapeutics Opioid Induced Constipation (OIC) Drug Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Nektar Therapeutics Opioid Induced Constipation (OIC) Drug Product Portfolio
  54. 6.9.5 Nektar Therapeutics Recent Developments
  55. 6.10 Ono Pharmaceutical
  56. 6.10.1 Ono Pharmaceutical Company Information
  57. 6.10.2 Ono Pharmaceutical Business Overview
  58. 6.10.3 Ono Pharmaceutical Opioid Induced Constipation (OIC) Drug Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Ono Pharmaceutical Opioid Induced Constipation (OIC) Drug Product Portfolio
  60. 6.10.5 Ono Pharmaceutical Recent Developments
  61. 6.11 Progenics Pharmaceuticals
  62. 6.11.1 Progenics Pharmaceuticals Company Information
  63. 6.11.2 Progenics Pharmaceuticals Business Overview
  64. 6.11.3 Progenics Pharmaceuticals Opioid Induced Constipation (OIC) Drug Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Progenics Pharmaceuticals Opioid Induced Constipation (OIC) Drug Product Portfolio
  66. 6.11.5 Progenics Pharmaceuticals Recent Developments
  67. 6.12 Purdue Pharma
  68. 6.12.1 Purdue Pharma Company Information
  69. 6.12.2 Purdue Pharma Business Overview
  70. 6.12.3 Purdue Pharma Opioid Induced Constipation (OIC) Drug Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 Purdue Pharma Opioid Induced Constipation (OIC) Drug Product Portfolio
  72. 6.12.5 Purdue Pharma Recent Developments
  73. 6.13 S.L.A. Pharma
  74. 6.13.1 S.L.A. Pharma Company Information
  75. 6.13.2 S.L.A. Pharma Business Overview
  76. 6.13.3 S.L.A. Pharma Opioid Induced Constipation (OIC) Drug Sales, Revenue and Gross Margin (2021-2026)
  77. 6.13.4 S.L.A. Pharma Opioid Induced Constipation (OIC) Drug Product Portfolio
  78. 6.13.5 S.L.A. Pharma Recent Developments
  79. 6.14 Shionogi &
  80. 6.14.1 Shionogi & Company Information
  81. 6.14.2 Shionogi & Business Overview
  82. 6.14.3 Shionogi & Opioid Induced Constipation (OIC) Drug Sales, Revenue and Gross Margin (2021-2026)
  83. 6.14.4 Shionogi & Opioid Induced Constipation (OIC) Drug Product Portfolio
  84. 6.14.5 Shionogi & Recent Developments
  85. 6.15 Sucampo Pharmaceuticals
  86. 6.15.1 Sucampo Pharmaceuticals Company Information
  87. 6.15.2 Sucampo Pharmaceuticals Business Overview
  88. 6.15.3 Sucampo Pharmaceuticals Opioid Induced Constipation (OIC) Drug Sales, Revenue and Gross Margin (2021-2026)
  89. 6.15.4 Sucampo Pharmaceuticals Opioid Induced Constipation (OIC) Drug Product Portfolio
  90. 6.15.5 Sucampo Pharmaceuticals Recent Developments
  91. 6.16 Theravance Biopharma
  92. 6.16.1 Theravance Biopharma Company Information
  93. 6.16.2 Theravance Biopharma Business Overview
  94. 6.16.3 Theravance Biopharma Opioid Induced Constipation (OIC) Drug Sales, Revenue and Gross Margin (2021-2026)
  95. 6.16.4 Theravance Biopharma Opioid Induced Constipation (OIC) Drug Product Portfolio
  96. 6.16.5 Theravance Biopharma Recent Developments
  97. 6.17 Pfizer
  98. 6.17.1 Pfizer Company Information
  99. 6.17.2 Pfizer Business Overview
  100. 6.17.3 Pfizer Opioid Induced Constipation (OIC) Drug Sales, Revenue and Gross Margin (2021-2026)
  101. 6.17.4 Pfizer Opioid Induced Constipation (OIC) Drug Product Portfolio
  102. 6.17.5 Pfizer Recent Developments
  103. 6.18 Takeda Pharmaceutical Company Limited
  104. 6.18.1 Takeda Pharmaceutical Company Limited Company Information
  105. 6.18.2 Takeda Pharmaceutical Company Limited Business Overview
  106. 6.18.3 Takeda Pharmaceutical Company Limited Opioid Induced Constipation (OIC) Drug Sales, Revenue and Gross Margin (2021-2026)
  107. 6.18.4 Takeda Pharmaceutical Company Limited Opioid Induced Constipation (OIC) Drug Product Portfolio
  108. 6.18.5 Takeda Pharmaceutical Company Limited Recent Developments
7 North America by Country
  1. 7.1 North America Opioid Induced Constipation (OIC) Drug Sales by Country
  2. 7.1.1 North America Opioid Induced Constipation (OIC) Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Opioid Induced Constipation (OIC) Drug Sales by Country (2021-2026)
  4. 7.1.3 North America Opioid Induced Constipation (OIC) Drug Sales Forecast by Country (2027-2032)
  5. 7.2 North America Opioid Induced Constipation (OIC) Drug Market Size by Country
  6. 7.2.1 North America Opioid Induced Constipation (OIC) Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Opioid Induced Constipation (OIC) Drug Market Size by Country (2021-2026)
  8. 7.2.3 North America Opioid Induced Constipation (OIC) Drug Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Opioid Induced Constipation (OIC) Drug Sales by Country
  2. 8.1.1 Europe Opioid Induced Constipation (OIC) Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Opioid Induced Constipation (OIC) Drug Sales by Country (2021-2026)
  4. 8.1.3 Europe Opioid Induced Constipation (OIC) Drug Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Opioid Induced Constipation (OIC) Drug Market Size by Country
  6. 8.2.1 Europe Opioid Induced Constipation (OIC) Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Opioid Induced Constipation (OIC) Drug Market Size by Country (2021-2026)
  8. 8.2.3 Europe Opioid Induced Constipation (OIC) Drug Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Opioid Induced Constipation (OIC) Drug Sales by Country
  2. 9.1.1 Asia-Pacific Opioid Induced Constipation (OIC) Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Opioid Induced Constipation (OIC) Drug Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Opioid Induced Constipation (OIC) Drug Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Opioid Induced Constipation (OIC) Drug Market Size by Country
  6. 9.2.1 Asia-Pacific Opioid Induced Constipation (OIC) Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Opioid Induced Constipation (OIC) Drug Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Opioid Induced Constipation (OIC) Drug Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Opioid Induced Constipation (OIC) Drug Sales by Country
  2. 10.1.1 South America Opioid Induced Constipation (OIC) Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Opioid Induced Constipation (OIC) Drug Sales by Country (2021-2026)
  4. 10.1.3 South America Opioid Induced Constipation (OIC) Drug Sales Forecast by Country (2027-2032)
  5. 10.2 South America Opioid Induced Constipation (OIC) Drug Market Size by Country
  6. 10.2.1 South America Opioid Induced Constipation (OIC) Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Opioid Induced Constipation (OIC) Drug Market Size by Country (2021-2026)
  8. 10.2.3 South America Opioid Induced Constipation (OIC) Drug Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Opioid Induced Constipation (OIC) Drug Sales by Country
  2. 11.1.1 Middle East and Africa Opioid Induced Constipation (OIC) Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Opioid Induced Constipation (OIC) Drug Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Opioid Induced Constipation (OIC) Drug Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Opioid Induced Constipation (OIC) Drug Market Size by Country
  6. 11.2.1 Middle East and Africa Opioid Induced Constipation (OIC) Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Opioid Induced Constipation (OIC) Drug Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Opioid Induced Constipation (OIC) Drug Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Opioid Induced Constipation (OIC) Drug Value Chain Analysis
  2. 12.1.1 Opioid Induced Constipation (OIC) Drug Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Opioid Induced Constipation (OIC) Drug Production Mode & Process
  7. 12.2 Opioid Induced Constipation (OIC) Drug Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Opioid Induced Constipation (OIC) Drug Distributors
  10. 12.2.3 Opioid Induced Constipation (OIC) Drug Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst